Original Source: Anemia Market
Buy Now:Market Research
Browse all : Pharmaceuticals Market
GlobalData, the industry analysis specialist, has released its new report, "Anemia - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global Anemia market. The report identifies the key trends shaping and driving the global Anemia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Anemia sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
GlobalData valued the anemia market in 2009 at $10.4 billion, indicating a CAGR of 7.4% between 2001 and 2009. The main driver for the growth of the anemia market is the rapid utilization of Erythropoietin Stimulating Agents (ESAs) such as Aranesp (darbepoeitin alfa), Procrit (epoetin alfa), Epogen (epoetin alfa) and Neorecormon (epoetin beta). These therapies are biological in nature and the annual cost of anemia therapy with these drugs ranges between $3,000 and $8,000. The majority of these therapies were launched between 2001 and 2007 and as a result market growth was pronounced in that period. In 2007, safety concerns over the use of ESAs surfaced and this has led to a decline in sales of the drugs. Since then, growth in the anemia market has been declining. Between 2009 and 2017, the market is expected to decline further as there are no key promising therapies expected to enter the anemia market. Furthermore, biosimilars of ESAs have already entered the European market and are expected to enter the US market between 2009 and 2017. This factor is also expected to restrain the growth of the market.
Scope
The report provides information on the key drivers and challenges of the Anemia market. Its scope includes:
Annualized global Anemia market revenues data from 2001 to 2009, forecast for eight years to 2017.
Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as Erythropoesis Stimulating Agent, Oral HIF-PH inhibitor, TGF- beta inhibitors, Fetal globin gene expression stimulator, oral EPO inducers, EPO mimetic peptide.
Analysis of the current and future competition in the global Anemia market. Key market players covered are Amgen Inc, Roche, Jhonson & Jhonson, Vifor Inc, and Affymax.
Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Anemia therapeutics market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to:
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global Anemia market.
Buy Now:Market Research
Browse all : Pharmaceuticals Market
GlobalData, the industry analysis specialist, has released its new report, "Anemia - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global Anemia market. The report identifies the key trends shaping and driving the global Anemia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Anemia sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
GlobalData valued the anemia market in 2009 at $10.4 billion, indicating a CAGR of 7.4% between 2001 and 2009. The main driver for the growth of the anemia market is the rapid utilization of Erythropoietin Stimulating Agents (ESAs) such as Aranesp (darbepoeitin alfa), Procrit (epoetin alfa), Epogen (epoetin alfa) and Neorecormon (epoetin beta). These therapies are biological in nature and the annual cost of anemia therapy with these drugs ranges between $3,000 and $8,000. The majority of these therapies were launched between 2001 and 2007 and as a result market growth was pronounced in that period. In 2007, safety concerns over the use of ESAs surfaced and this has led to a decline in sales of the drugs. Since then, growth in the anemia market has been declining. Between 2009 and 2017, the market is expected to decline further as there are no key promising therapies expected to enter the anemia market. Furthermore, biosimilars of ESAs have already entered the European market and are expected to enter the US market between 2009 and 2017. This factor is also expected to restrain the growth of the market.
Scope
The report provides information on the key drivers and challenges of the Anemia market. Its scope includes:
Annualized global Anemia market revenues data from 2001 to 2009, forecast for eight years to 2017.
Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as Erythropoesis Stimulating Agent, Oral HIF-PH inhibitor, TGF- beta inhibitors, Fetal globin gene expression stimulator, oral EPO inducers, EPO mimetic peptide.
Analysis of the current and future competition in the global Anemia market. Key market players covered are Amgen Inc, Roche, Jhonson & Jhonson, Vifor Inc, and Affymax.
Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Anemia therapeutics market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to:
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global Anemia market.